

Curriculum Vitae

**CV must be written in English*

Personal Information



Title (i.e. Prof., Dr., etc.)	Prof.
Name (First / Middle / Last)	Joana Torres
Degree (i.e. MD, MSc, PhD, etc.)	MD, PhD
Country	Portugal
Affiliation	University of Lisbon, Hospital Beatriz Ângelo, Hospital da Luz

Educational Background and Professional Experience

Joana Torres completed her fellowship in Gastroenterology at Coimbra, Portugal. After post-doctoral training in Icahn School of Medicine at Mount Sinai, New York, she completed her PhD, and was appointed Auxiliary Professor in the University of Lisbon.

She is currently working in Hospital Beatriz Ângelo & Hospital da Luz, Lisbon, Portugal as a Consultant in Gastroenterology, where she is responsible for the IBD clinic, actively combining clinical practice with research and teaching. Her research focusses in populations at risk for IBD and in newly diagnosed IBD with the aim of finding predictors of IBD development and of disease course.

She is involved in several large projects aiming to find predictors of IBD and potentially to develop preventive interventions, such as the Predicts Study, the EARLY-CD study, the GlycanTrigger project and the Large European Union funded, the INTERCEPT project.

She has served in the European Crohn and Colitis organization (ECCO) as a member and chair of the Guideline Committee (GuiCom). She is currently a member of the Gastroenterology Portuguese Society Board, and from the United European Gastroenterology (UEG) Public Affairs Committee. She is Associate Editor for Clinical Gastroenterology & Hepatology. She has received the ECCO Travel Award, the International Organization for the Study of Inflammatory Bowel Disease (IOIBD) Travel Award and the National Gastroenterology Award, and has received the UEG Rising Star Award in 2023 for her work in pre-clinical IBD.

Main Scientific Publications (relevant to the content of the talk)

1. Torres J, Mahadevan U. Ustekinumab and Vedolizumab Safety and Clearance in Pregnancy With Inflammatory Bowel Disease: Stop the Disease, Not the Drug! Clin Gastroenterol Hepatol 2025;23:28-30.
2. Tarassishin L, Kim T, Hu J, et al. Elevated Fecal Lipocalin-2 Levels During Early Life Are Associated with Maternal Inflammatory Bowel Disease Diagnosis. Dig Dis Sci 2025;70:1150-1159.
3. Ribeiro-Mourão F, Agrawal M, Torres J, et al. Intervention(s) in the Early-Life Period to Modulate Inflammatory Bowel Disease Risk: What Could Be the Impact? Inflamm Bowel Dis

AOCC 2026

IMKASID 2026

JUNE 25 (Thu.) - 27 (Sat.), 2026 | COEX, SEOUL, KOREA
2025;31:S27-s40.



4. Mahadevan U, Seow CH, Barnes EL, et al. Global consensus statement on the management of pregnancy in inflammatory bowel disease. *Gut* 2025.
5. Kim T, Nicoletti P, Estevinho MM, et al. Association Between Maternal IBD -Related Antibodies and Early Life Gut Inflammatory Status and Microbiota Composition: Insights from Cord Blood. *J Inflamm Res* 2025;18:16009 -16022.
6. Casanova MJ, Gisbert JP, Amiot A, et al. International Survey of Gastroenterologists on Managing Inflammatory Bowel Disease During Pregnancy and Lactation: Current State and the Necessity for Improvements. *United European Gastroenterol J* 2025.
7. Bonfils L, Poulsen G, Agrawal M, et al. Impact of prenatal and postnatal maternal IBD status on offspring's risk of IBD: a population -based cohort study. *Gut* 2025;74:206 -213.
8. Torres J, Chaparro M, Julsgaard M, et al. European Crohn's and Colitis Guidelines on Sexuality, Fertility, Pregnancy, and Lactation. *J Crohns Colitis* 2023;17:1 -27.
9. Shah SC, Tarassishin L, Eisele C, et al. Breastfeeding Is Associated with Lower Likelihood of Helicobacter Pylori Colonization in Babies, Based on a Prospective USA Maternal -Infant Cohort. *Dig Dis Sci* 2022;67:5149-5157.
10. Kim ES, Tarassishin L, Eisele C, et al. Longitudinal Changes in Fecal Calprotectin Levels Among Pregnant Women With and Without Inflammatory Bowel Disease and Their Babies. *Gastroenterology* 2021;160:1118-1130.e3.
11. Frias Gomes C, Narula N, Morão B, et al. Mode of Delivery Does Not Affect the Risk of Inflammatory Bowel Disease. *Dig Dis Sci* 2021;66:398-407.
12. Agrawal M, Sabino J, Frias-Gomes C, et al. Early life exposures and the risk of inflammatory bowel disease: Systematic review and meta -analyses. *EClinicalMedicine* 2021;36:100884.
13. Torres J, Hu J, Seki A, et al. Infants born to mothers with IBD present with altered gut microbiome that transfers abnormalities of the adaptive immune system to germ -free mice. *Gut* 2020;69:42-51.
14. Peter I, Maldonado-Contreras A, Eisele C, et al. A dietary intervention to improve the microbiome composition of pregnant women with Crohn's disease and their offspring: The MELODY (Modulating Early Life Microbiome through Dietary Intervention in Pregnanc y) trial design. *Contemp Clin Trials Commun* 2020;18:100573.
15. Nair N, Austin C, Curtin P, et al. Association Between Early -life Exposures and Inflammatory Bowel Diseases, Based on Analyses of Deciduous Teeth. *Gastroenterology* 2020;159:383 -385.
16. Gomes CF, Sousa M, Lourenço I, et al. Gastrointestinal diseases during pregnancy: what does the gastroenterologist need to know? *Ann Gastroenterol* 2018;31:385 -394.
17. Ellul P, Zammita SC, Katsanos KH, et al. Perception of Reproductive Health in Women with Inflammatory Bowel Disease. *J Crohns Colitis* 2016;10:886 -91.